Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Antineoplastic Agents, Alkylating
/ adverse effects
Blood Platelets
/ drug effects
Brain Neoplasms
/ drug therapy
Drug Compounding
Drugs, Generic
/ adverse effects
Female
Glioblastoma
/ drug therapy
Humans
Kinetics
Male
Middle Aged
Platelet Count
Retrospective Studies
Risk Assessment
Risk Factors
Temozolomide
/ adverse effects
Thrombocytopenia
/ blood
Treatment Outcome
chemo-induced thrombocytopenia
drug safety
generic drug
glioblastoma
temozolomide
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
06
2019
revised:
24
12
2019
accepted:
24
01
2020
pubmed:
30
1
2020
medline:
21
4
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma. We aimed to compare early platelet concentration kinetics, hematological safety profile, and impact on survival following the initiation of either the brand-name or a generic TMZ formulation. A retrospective trial was conducted in patients suffering from newly diagnosed glioblastoma. Patients were treated with TMZ at 75 mg/m
Substances chimiques
Antineoplastic Agents, Alkylating
0
Drugs, Generic
0
Temozolomide
YF1K15M17Y
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
484-494Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Ostrom Q.T., Bauchet L., Davis F.G. et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncology. (2014) 16(7) 896-913.
Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. (2015) 136(5) E359-E386.
Ostrom Q.T., Gittleman H., Liao P. et al. Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncology. (2017) 19(suppl_5) v1-v88.
Stupp R., Mason W.P., van den Bent M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10) 987-996.
Lukas R.V., Wainwright D.A., Ladomersky E., Sachdev S., Sonabend A.M., Stupp R. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park, NY). (2019) 33(3) 91-100.
Ostrom Q.T., Cote D.J., Ascha M., Kruchko C., Barnholtz-Sloan J.S. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA. Oncol. (2018) 21 e181789.
Skardelly M., Dangel E., Gohde J. et al. Prolonged temozolomide maintenance therapy in newly diagnosed glioblastoma. Oncologist. (2017) 22(5) 570-575.
Gupta T., Mohanty S., Moiyadi A., Jalali R. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit. Clin. Neurol. Neurosurg. (2013) 115(9) 1814-9.
Chinot O.L., Wick W., Mason W. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. (2014) 370(8) 709-22.
Gilbert M.R., Dignam J.J., Armstrong T.S. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. (2014) 370(8) 699-708.
Weller M., Butowski N., Tran D.D. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet. Oncol. (2017) 18(10) 1373-85.
Stupp R., Hegi M.E., Gorlia T. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet. Oncol. (2014) 15(10) 1100-1108.
Stupp R., Taillibert S., Kanner A.A. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA (2015) 314(23) 2535-2543.
Oike T., Ohno T., Noda S. et al. Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy. J. Radiat. Res. (2013) 54(3) 474-478.
Ochi N., Yamane H., Hotta K. et al. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Drug. Des. Devel. Ther. (2014) 8 2401-2408.
Niho S., Yamanaka T., Umemura S. et al. Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. Jpn. J. Clin. Oncol. (2013) 43(4) 390-395.
Fujii H., Iihara H., Yasuda K. et al. Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy. Med. Oncol. (2011) 28(2) 488-493.
Fontanilles M., Marguet F., Alexandru C. et al. Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. Support. Care. Cancer (2018) 27 477-484.
Niyazi M., Brada M., Chalmers A.J. et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother. Oncol. (2016) 118(1) 35-42.
Chessel D., Dufour A.B., Thioulouse J.The ade4 package - I: one-table methods (2004). R News 4:5-10 [Internet]. Available from: http://pbil.univ-lyon1.fr/JTHome/ref/ade4-Rnews.pdf
Huang R.Y., Rahman R., Ballman K.V. et al. The impact of T2/FLAIR evaluation per RANO criteria on response assessment of recurrent glioblastoma patients treated with bevacizumab. Clin. Cancer Res. (2016) 22(3) 575-581.
U.S. Department of Health and Human Services Cfdear. Approved Drug Products with Therapeutic Equivalence Evaluations 39th Edition [Internet] (2019). Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ucm071436.pdf
Davit B.M., Nwakama P.E., Buehler G.J. et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann. Pharmacother. (2009) 43(10) 1583-1597.
Chambord J., Henny F., Salleron J. et al. Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®). J. Clin. Pharm. Ther. (2019) 44(3) 372-380.
Sekine I., Kubota K., Tamura Y. et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci. (2011) 102(1) 162-165.
Letarte N., Gabay M.P., Bressler L.R., Long K.E., Stachnik J.M., Villano J.L. Analyzing temozolomide medication errors: potentially fatal. J. Neurooncol. (2014) 120(1) 111-115.
Armstrong T.S., Cao Y., Scheurer M.E. et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro-oncology. (2009) 11(6) 825-832.
Chang Y., Yang Z.-Y., Li G.-L. et al. Correlations between radiation dose in bone marrow and hematological toxicity in patients with cervical cancer: a comparison of 3DCRT, IMRT, and RapidARC. Int. J. Gynecol. Cancer. (2016) 26(4) 770-776.
Hui B., Zhang Y., Shi F. et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy. Int. J. Gynecol. Cancer. (2014) 24(9) 1648-1652.
Erpolat O.P., Alco G., Caglar H.B. et al. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. Eur. J. Gynaecol. Oncol. (2014) 35(1) 62-66.
Byun H.K., Kim N., Yoon H.I. et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat. Oncol. (2019) 14(1) 51.
Gouérant S., Leheurteur M., Chaker M. et al. A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res. (2013) 33(12) 5655-5662.
Ostermann S., Csajka C., Buclin T. et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. (2004) 10(11) 3728-3736.
Shachar S.S., Deal A.M., Weinberg M. et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin. Cancer Res. (2017) 23(14) 3537-3543.
Reid J.M., Stevens D.C., Rubin J., Ames M.M. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res. (1997) 3(12 Pt 1) 2393-2398.
Lombardi G., Rumiato E., Bertorelle R. et al. Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am. J. Clin. Oncol. (2015) 38 514-519.
Altinoz M.A., Elmaci I., Bolukbasi F.H. et al. MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. J. Chemother. (2017) 23 1-7.